Jeff Yass’s Pyxis Oncology PYXS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.28M Buy
+548,145
New +$1.66M ﹤0.01% 7357
2026
Q2
– Sell
-41,201
Closed -$78.8K – 14299
2026
Q1
$60.2K Sell
41,201
-67,213
-62% -$101K ﹤0.01% 12581
2025
Q4
$125K Sell
108,414
-29,117
-21% -$103K ﹤0.01% 11324
2025
Q3
$305K Buy
137,531
+23,172
+20% +$33.4K ﹤0.01% 10070
2025
Q2
$126K Buy
114,359
+49,471
+76% +$55.7K ﹤0.01% 11638
2025
Q1
$63.6K Sell
64,888
-3,087
-5% -$4.12K ﹤0.01% 11778
2024
Q4
$106K Sell
67,975
-17,843
-21% -$51.5K ﹤0.01% 11301
2024
Q3
$315K Sell
85,818
-29,877
-26% -$105K ﹤0.01% 9495
2024
Q2
$383K Buy
115,695
+46,244
+67% +$194K ﹤0.01% 8899
2024
Q1
$296K Buy
69,451
+57,628
+487% +$242K ﹤0.01% 9728
2023
Q4
$21.3K Sell
11,823
-20,730
-64% -$35.5K ﹤0.01% 11960
2023
Q3
$64.8K Sell
32,553
-11,052
-25% -$25.6K ﹤0.01% 11178
2023
Q2
$112K Buy
+43,605
New +$138K ﹤0.01% 10873
2022
Q3
– Sell
-14,466
Closed -$34K – 13940
2022
Q2
$34K Buy
+14,466
New +$38.5K ﹤0.01% 12165

Other funds holding PYXS

Jeff Yass's PYXS Position: Q3 2026 in Review

Jeff Yass opened a new position in Pyxis Oncology (PYXS) in Q3 2026: 548,145 shares worth $1.28M. The stake represents ﹤0.01% of the portfolio and ranks #7357 among its holdings. This is a return to the name: Jeff Yass previously reported a position in PYXS as recently as Q1 2026.

Jeff Yass first reported a position in PYXS in Q2 2022 and has held it in 14 quarters since. 101 funds tracked by Wall St. Rank hold PYXS as of Q3 2026.

  • Jeff Yass held 548,145 shares of Pyxis Oncology worth $1.28M as of Q3 2026.
  • Pyxis Oncology was a new Jeff Yass position in Q3 2026.
  • Pyxis Oncology made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #7357 holding.
  • Jeff Yass first reported a position in Pyxis Oncology in Q2 2022 and has held it in 14 quarters since.
  • 101 funds tracked by Wall St. Rank held Pyxis Oncology as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.